BioSpace News Archive

The collaboration will establish a study protocol with an initial focus on breast cancer to provide the regulatory agency with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease.

According to BioEnterprise, the Midwest saw a significant increase in life sciences investment last year. In Cincinnati itself, there were 16 different investments totaling $81.8 million.

Biopharma companies from across Europe, Asia and North America share updates on business decisions and pipeline development.

Teijin Pharma Limited announced that it has launched Revcovi® 2.4 mg for intramuscular injection [Elapegademase], effective immediately.

A two-year old patient at the Royal Manchester Children’s Hospital (RMCH) is the first in the world to receive a pioneering new ex vivogene therapy treatment using lentiviral vector-modified autologous stem cells for the rare and life-limiting genetic condition, Mucopolysaccharidosis IIIA (MPSIIIA).

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway

Upon approval by the shareholders, ASIT biotech expects to raise between €9M and €12M of convertible notes to finance its focused development

Medtronic plc, the global leader in medical technology, announced that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, California.

Probiodrug AG, announces that its shareholders approved all resolutions proposed by the Company’s Management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, May 29, 2019